Inhaler Corticosteroid Device Market Report 2025

The inhaler corticosteroid device market size has grown strongly in recent years. It will grow from $15.75 billion in 2024 to $16.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period was driven by rising healthcare spending, a growing elderly population, favorable government policies, ongoing research and development efforts, and higher disposable incomes.

The inhaler corticosteroid device market size is expected to see strong growth in the next few years. It will grow to $21.77 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth during the forecast period is driven by an increase in respiratory disorders, heightened awareness of respiratory health, substantial investments in respiratory technologies, an expanding focus on health education, and a rise in smoking addiction. Key trends expected to influence this period include the adoption of smart technologies, development of combination therapies, introduction of digital inhalers with real-time monitoring, advancements in inhaler design, and the use of data analytics in inhaler devices.

The rising prevalence of respiratory diseases is expected to drive the growth of the inhaler corticosteroid device market in the coming years. Respiratory diseases encompass a variety of conditions affecting the lungs and airways, which impair proper and efficient breathing. The increase in respiratory diseases is attributed to growing air pollution, exposing people to harmful particles that damage lung tissue and trigger chronic conditions such as asthma and bronchitis. Inhaler corticosteroid devices treat respiratory diseases by delivering anti-inflammatory medication directly to the lungs, helping to reduce inflammation and improve breathing. For example, in June 2025, the UK’s Office for Health Improvement and Disparities reported that in the financial year ending 2024, England recorded 854,922 emergency hospital admissions for respiratory diseases, corresponding to a rate of 1,428 (ranging from 1,424 to 1,432) per 100,000 population - a 7% increase compared to the previous year. Therefore, the growing prevalence of respiratory diseases is fueling the expansion of the inhaler corticosteroid device market.

Leading companies in the inhaler corticosteroid device market are focusing on launching innovative solutions, such as rescue inhalers that combine albuterol and budesonide to improve treatment efficacy and provide patients with a more convenient, dual-action therapy within a single device. An inhaler combining albuterol and budesonide is a dual-action rescue inhaler that delivers both a bronchodilator (albuterol) to rapidly open airways and a corticosteroid (budesonide) to reduce inflammation, offering quick symptom relief and long-term asthma control in one device. For instance, in January 2024, AstraZeneca PLC, a UK-based pharmaceutical company, introduced AIRSUPRA, the first and only FDA-approved rescue inhaler combining albuterol and budesonide for adults with asthma. This inhaler is intended for as-needed use to relieve acute bronchoconstriction symptoms and reduce airway inflammation, thereby lowering the risk of severe asthma attacks. It represents a novel approach by combining a short-acting beta2-agonist (albuterol) with an inhaled corticosteroid (budesonide) in a single inhaler, with approval based on clinical trials demonstrating its superiority over albuterol alone in preventing asthma exacerbations.

In March 2022, Sandoz Group AG, a Switzerland-based company specializing in generic pharmaceuticals and biosimilars, acquired Coalesce Product Development Limited for an undisclosed amount. This acquisition aims to strengthen Sandoz’s position in developing and delivering complex, high-quality respiratory therapies by incorporating Coalesce’s advanced expertise in innovative drug delivery device design and manufacturing. This supports Sandoz’s broader strategy to expand its value-added medicines portfolio and reinforce its commitment to patient-focused, integrated treatment solutions. Coalesce Product Development Limited is a UK-based medical device company specializing in designing and developing respiratory drug delivery devices, including inhalers for inhaled corticosteroids.

Major players in the inhaler corticosteroid device market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Teijin Pharma Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Mundipharma International Limited, Lupin Limited, Zydus Lifesciences Limited, Recipharm AB, Glenmark Pharmaceuticals Limited, Orion Corporation, Beximco Pharmaceuticals Limited, PARI Medical Holding GmbH, and Kos Pharmaceuticals Inc.

North America was the largest region in the inhaler corticosteroid device market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inhaler corticosteroid device report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the inhaler corticosteroid device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The inhaler corticosteroid device market consists of sales of nebulizer solutions, manual soft mist inhalers, conventional metered-dose inhalers, and combination inhalers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The inhaler corticosteroid device market research report is one of a series of new reports that provides inhaler corticosteroid device market statistics, including inhaler corticosteroid device industry global market size, regional shares, competitors with an inhaler corticosteroid device market share, detailed inhaler corticosteroid device market segments, market trends and opportunities, and any further data you may need to thrive in the inhaler corticosteroid device industry. This inhaler corticosteroid device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An inhaler corticosteroid device is a specialized medical instrument designed to deliver anti-inflammatory corticosteroid medication directly into the lungs. This targeted delivery reduces swelling and irritation in the airways caused by chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). By acting locally in the lungs, these devices help control and prevent symptoms like wheezing, shortness of breath, and coughing, while limiting the systemic side effects often associated with oral corticosteroids.

The primary types of inhaler corticosteroid devices include metered-dose inhalers, dry powder inhalers, and soft mist inhalers. Metered-dose inhalers (MDIs) are portable devices that release a precise, measured dose of medication into the lungs as an aerosol. These inhalers use various drug formulations such as fluticasone propionate, budesonide, beclomethasone, and mometasone furoate. They are distributed through online and retail pharmacies, direct sales, and hospital pharmacies. These devices are widely used for managing conditions like asthma and COPD, with end users including hospitals, home care providers, specialty clinics, and others.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.